Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentoxol is a brand of flupenthixol hydrochloride, a typical antipsychotic belonging to the thioxanthene class. Developed and marketed by Scotmann Pharmaceuticals, it is primarily indicated for the treatment of psychosis and schizophrenia. Flupenthixol acts as an antagonist at dopamine D1 and D2 receptors, as well as serotonin 5-HT2 receptors, which helps alleviate the positive symptoms of schizophrenia. It is also known for its activating or alerting properties at lower doses, making it useful for patients with apathy or withdrawal. In some clinical contexts, it is also utilized for its antidepressant and anxiolytic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flupenthixol.